| Heading: |
Drugs: Prices |
| Question ID: |
1811529 |
| UIN: |
59052 |
| House: |
Commons |
| Date tabled: |
2025-06-11 |
| Asking Member ID: |
4495 |
| Asking Member display name: |
Kit Malthouse
|
| Asking Member handle: |
kitmalthouse
|
| Asking Member Twitter reference: |
@kitmalthouse
|
| Member interest: |
true |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the (a) voluntary scheme for branded medicines pricing, access and growth and (b) statutory scheme payment rates on attracting pharmaceu |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-19 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Life sciences is a key growth-driving sector and is a core part of our modern Industrial Strategy. The 2024 Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) introduced, for the first time, an approximately £400 million industry-funded VPAG... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |